News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Adolor Corporation Expands Phase 2 Opioid Induced Constipation Program
January 10, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(BUSINESS WIRE)--Adolor Corporation (NasdaqGM: ADLR) today announced that it is initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain patients suffering from opioid-induced constipation (OIC).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
Drug Development
India’s life sciences sector at turning point for innovation: Report
July 17, 2026
·
2 min read
·
Angela Gabriel
IPO
2026 IPO stock tracker: How newly public biotechs are performing
July 17, 2026
·
1 min read
·
Gabrielle Masson
Business
GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail
July 17, 2026
·
1 min read
·
Tristan Manalac
Cardiovascular disease
Insmed moves closer to $6B opportunity as PAH drug shows long-term durability
July 17, 2026
·
2 min read
·
Tristan Manalac
